Amphastar (AMPH) Q2 FY26 earnings call

Amphastar delivered improved financial performance in Q2 FY26, driven by continued demand for key commercial products and successful new launches. The company is actively advancing its complex generic and proprietary pipelines, while also addressing an FDA warning letter at its IMS facility and navigating competitive pressures on certain products. Management reaffirmed its full-year corporate sales guidance.